Meanwhile, as a prognostic marker, low BRCA1 expression correlated with improved survival in advanced ovarian cancer who received platinum-based chemotherapy [27] and high BRCA1 expression correlated with longer mOS in gastric cancer patients treated with second-line docetaxel-based chemotherapy after first-line FOLFOX chemotherapy [29]. Here, BRCA1 is linked to ovarian carcinoma.